Drug delivery systems using microneedle arrays are of great interest to pharmaceutical companies who would like to alleviate the discomfort of the standard hypodermic needle with an easy to administer, painless drug delivery method. Many companies are developing microneedle technology, targeting a slice of the $18bn drug delivery device market. The microneedles range from hollow or coated steel arrays to biodegradable polymer needles that dissolve once injected.
Microneedle developers aim to design devices that are effective at penetrating the surface layer of skin, known as the stratum corneum, to deliver drugs to the dermis, whilst being short and narrow enough to avoid stimulating the dermal nerves and causing discomfort. It is important to understand how a change in microneedle design and application method affects the device performance.
According to the authors of the paper, "The successful use of OCT in this study could prove to be a key development for polymeric micro-needle research, accelerating their commercial exploitation."
"The VivoSight system is a unique tool for transdermal drug delivery development. It is the only clinical technology that can image the needles in situ, in real time," said Dr Daniel Woods, Senior Imaging Scientist at Michelson Diagnostics Ltd., adding "The high resolution and extended penetration depth of VivoSight mean that researchers can really understand how the needles interact with the skin."
About Michelson Diagnostics
Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography. The technology provides real time images of up to 2mm into tissue with a resolution of better than 10 microns. The company's products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including dermatology, developmental biology and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Applications of VivoSight include non-melanoma skin cancer screening and guiding skin cancer surgery.
Further information about Michelson Diagnostics is available on the Internet at http://www.md-ltd.co.uk/ or by email to [email protected]